Solid Biosciences (SLDB) EBIT Margin (2022)
Quarterly results put EBIT Margin at 411.44% for Q2 2022, changed N/A from a year ago — trailing twelve months through Jun 2023 was 1857.21% (down 43984.0% YoY), and the annual figure for FY2022 was 1315.2%, down 78470.0%.
Solid Biosciences has reported EBIT Margin over the past 1 years, most recently at 411.44% for Q2 2022.
- EBIT Margin reached 411.44% in Q2 2022 per SLDB's latest filing.
- Across five years, EBIT Margin topped out at 411.44% in Q2 2022 and bottomed at 411.44% in Q2 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 38.10% |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 17.83% |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 23.02% |
| 10 | Solid Biosciences | 713.77 Mn | 333.09 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | -411.44% |